Module 4: Drug-resistant tuberculosis treatment
Module 4: Drug-resistant tuberculosis treatment
Table of Content (Online Version) :
- Acknowledgements
- Abbreviations and acronyms
- 1. Introduction
- 2. Commonly used terms and key definitions in drug-resistant TB treatment
- 3. Key considerations in drugresistant TB treatment
- 4. Regimen for rifampicin-susceptible and isoniazid-resistant TB
- 5. The shorter all-oral bedaquiline-containing regimen for MDR/RR-TB
-
6. Longer regimens for MDR/RR-TB
- 6.1 Eligibility
- 6.2 Medicines used in longer MDR-TB treatment regimens
- 6.3 Composition of the longer MDR-TB regimens
- 6.4 Prolonged use of bedaquiline and concurrent use of bedaquiline and delamanid
- 6.5 Dosage of the longer MDR-TB regimen components
- 6.6 Duration of the longer MDR-TB regimens
- 6.7 Key subgroups
- 6.8 Treatment monitoring
- 7. The bedaquiline, pretomanid and linezolid (BPaL) regimen for MDR-TB with additional fluoroquinolone resistance
- 8. Adjuncts to MDR-TB treatment
- 9. Patient support to enable adherence to treatment
- 10. Programmatic implementation of MDR-TB regimens
- References
- Annex I: Dosage by weight band for medicines used in multidrug-resistant TB regimens, adults and children
VIEW PDF VERSION